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A B S T R A C T
Surgical therapy for the treatment of heart failure is a relatively young solution to 
a problem that has overwhelmed civilizations dating back to the First Dynasty. As 
medical therapy is limited by the progression of disease, and as organ replacement 
is limited by the shortage of donation for a heart transplant, assisted circulation has 
emerged as one of the most promising treatments of the failing heart in our era. The 
focus of this article will be to review the history and future of the Novacor Left Ven-
tricular Assist System (LVAS) as it relates to the failing heart; the story of how the 
innovator, the researcher, the engineer, and the surgeon have come together to offer a 
surgical solution to a medical problem of inconceivable scope.
I N T R O D U C T I O N
Despite centuries of enormous multi-disciplinary medical and technological ad-
vance, in 2006 nearly two thousand Americans died of cardiovascular disease each day, 
averaging 1 death every 35 seconds, and claiming more lives than the next 4 leading 
causes of death combined.1 In 2007, one in 30 female deaths was from breast cancer, 
while 1 in 2.6 was from cardiovascular disease.2 The prevalence of heart failure in our 
population is a staggering 5 million in the United States, and 6.5 million in Europe. 
Furthermore, based on the 44-year follow-up of the National Heart, Blood, and Lungs 
Institute Framingham Heart Study, 80% of men and 70% of women under age 65 who 
have heart failure will die within 8 years.3
Circa 1500 B.C. on the West Bank of the Nile in the necropolis of ancient Thebes, 
the Ebers Papyrus documents Egyptian priest-physicians using the sea onion or squill 
to treat excess blood in the heart and lungs.4-7 Medicinal plants for the treatment of 
“dropsy” were favored by Hippocrates, the subject of a treatise by Pythagorus, and the 
foundation of our current medical therapy as highlighted by the utilization of digitalis 
from the foxglove flower in the late 1700s.4-7 With the advent of cardiopulmonary bypass 
two centuries later, the transition to potential surgical alternatives was fully realized 
with the first orthotopic heart transplantation by Barnard in 1967.8,9 Yet as medical 
therapy is limited by the progression of disease, and as organ replacement is limited by 
the shortage of donation, assisted circulation has emerged as one of the most promis-
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ing treatments of the failing heart in our era.10,11 The evolution 
continues, beginning as a temporizing bridge-to-transplanta-
tion, and developing into destination therapy, an apt name in 
a journey to treat an ailment that was first encountered several 
hundred years before the birth of Christ.
B O D Y  O F  R E V I E W
A variety of technologies have been designed to mechani-
cally assist circulation.10,11 All of these systems provide energy 
for the forward flow of blood in the body to relieve the left 
heart of this charge, while allowing differing degrees of pres-
sure and volume unloading of the ventricle. The devices as well 
as their power sources may be implanted internally or placed in 
a paracorporeal position. Both electric and pneumatic driven 
mechanisms are available, and flow characteristics can be cat-
egorized as pulsatile or non-pulsatile in nature. Devices may 
be utilized as a temporizing measure for bridge-to-transplant 
(BTT) therapy while awaiting organ availability, while some 
may be implanted as an alternative to transplantation, which 
is designated as destination therapy (DT) for those patients 
with poor candidacy for organ replacement.
The Novacor® Left Ventricular Assist System (WorldHeart 
Inc., Oakland, California) has emerged as one of the most 
reliable devices in this competitive market.12-18 Scientists in 
Berkeley, CA began developing the system in 1969 based on a 
pulsed-solenoid driver concept, and 15 years later the world’s 
first human implant and successful bridge-to-transplant opera-
tion was successfully performed with the Novacor LVAS. In 
1994, the device received regulatory approval for European 
Commercialization (CE Mark) without restriction as to the 
indication for use, and in 1998, Food and Drug Administra-
tion (FDA) approval for U.S. sales as a bridge-to-transplant 
system was acquired.
The WorldHeart Novacor LVAS is an electro-magnetically 
driven device that has an implantable pump and paracorpor-
eal power source that provides pulsatile flow for circulatory 
support (Fig. 1). Blood enters the device through an inflow 
conduit connected to the recipient’s left ventricle. Circulation 
is supported as the pump ejects blood in parallel through its 
own outflow conduit into the arterial system, most commonly 
the distal portion of the ascending aorta. The system is com-
pletely self-regulating, automatically adjusting its beat rate 
and stroke volume in response to the recipient’s changing 
hemodynamic requirements.
The power source is an external controller that regulates 
pumping action and monitors system function, alarming for 
out-of-range operation or fault conditions (Fig. 2). A small 
tube, often referred to as the drive line, contains control and 
power wires and traverses the patient’s skin to connect the 
implanted pump to the external controller. Two rechargeable 
batteries provide power to the controller (Fig. 3), and these 
FIGURE 1. The Novacor LVAS I implantable system. Blood en-
ters the device through the inflow conduit from the left ventricle, 
and pumps blood to the body through the outflow conduit to the 
ascending aorta.
FIGURE 2. The external Controller regulates pumping action 
and monitors system function.
portable power packs may be worn on a belt or carried in a vest, 
shoulder bag, or backpack. The nickel-metal hydride power 
packs have been recently enhanced to last approximately 8 
hours per pair at an output of 6 L/min. A personal monitor, 
designed for in-home use, supplies power to the Novacor when 
the recipient is sleeping, and also evaluates device function, 
providing an alarm and instructions in the event of a detected 
fault. A standby power source provides power to the monitor 
in case of an AC power outage.
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Implantation is performed with the assistance of cardi-
opulmonary bypass through a median sternotomy incision 
extended halfway to the umbilicus. Most commonly, a pocket 
for the pump is developed posterior to the left rectus abdomi-
nus muscle and anterior to the left posterior rectus sheath 
from the costal margin to the iliac crest. The inflow conduit 
is tunneled from the pump pocket to the apex of the heart in 
the pericardial cavity and implanted in the left ventricle. The 
outflow conduit courses along the right pleural space to con-
nect the pump to the ascending aorta. Finally, the drive line 
is tunneled through the subcutaneous tissue to exit the skin 
in the right lower quadrant of the abdomen, connecting the 
pump to the external controller. The patient is then weaned off 
of cardiopulmonary bypass and onto Novacor left ventricular 
assistance.
Left heart hemodynamic indices are uniformly improved 
with the institution of Novacor circulatory support, as evi-
denced by statistically significant increases in cardiac output 
and decreased pulmonary capillary wedge pressures, usually 
within 24 hours of implantation.12-15,18 Functional right heart 
recovery is not as consistently realized, but most trials demon-
strate a trend toward significantly improved right ventricular 
ejection fraction and decreased central venous pressure and 
pulmonary vascular resistance with the Novacor system.12,13,15,17 
In patients receiving LVAS assistance for more than 20 days, 
improved end organ function has been documented with 
improved hepatic and renal function prior to transplanta-
tion.12,17
Early in the Novacor experience, thromboembolism was a 
major concern during mechanical circulatory support. Larger 
studies have documented the rate of embolic cerebrovascular 
accident (CVA) as high as 29.0% in previous years.12-14 A recent 
review of the collective experience among the 8 most active 
centers in North America and Europe demonstrates that the 
current rate of embolic stroke has been reliably reduced to 
5.3% (Fig. 4).20 While modification of anticoagulation proto-
cols has been instituted, the most likely explanation for this 
approximately 85% decrease in the rate of cerebrovascular 
events is the revision of the Novacor inflow conduit with a 
material that is less thrombogenic.15,18,19 Other complications 
such as infection have also become less frequent with subtle 
changes in operative techniques such as immobilization of 
the driveline at the skin exit site, meticulous tailoring of the 
pump pocket, and aggressive drainage of potential sites of 
fluid collection in the early peri-operative period.15,18,21 In strik-
ing contrast to other systems, only 1.4% of Novacor devices 
have required replacement over their lifespan, indicating an 
unparalleled degree of reliability.16
Much of the earlier literature addressing survival outcomes 
focused on comparisons between the two major pulsatile 
pumps, the Novacor LVAS and the Thoratec HeartMate 
Implantable Vented Electric System (Thoratec Corportation, 
Pleasanton, CA). A prospectively designed trial at a single 
center enrolled 40 patients and found that survival to trans-
plantation was 65% for the Novacor group and 60% for the 
HeartMate recipients.22 A more recent study has reproduced 
this trend with a 69% survival to transplant with patients re-
ceiving the Novacor device, and a 61% survival in recipients 
of the HeartMate system. Kaplan-Meyer 5-month survival 
post-LVAD was 89% for the Novacor group and 83% for the 
HeartMate group.23 There have been over 1700 successful 
Novacor implantations worldwide with multiple reports of con-
tinued use for over four years without device malfunction.15,24 
In July of 2006, a patient in Tennessee entered his sixth year 
of continuous support with his original Novacor LVAS.16 At 
the time of publication, this is the longest documented period 
of circulatory assistance without the need for device exchange 
among all pulsatile systems worldwide.
C O N C L U S I O N
For patients awaiting transplantation, the Novacor LVAS 
FIGURE 4. Incidence of embolic cerebrovascular accidents (eC-
VA) with different types of inflow conduits.FIGURE 3. Rechargeable nickel-metal hydride (Ni-MH) battery 
lasts approximately six hours per pair (at an output of 6L/min).
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has demonstrated consistently favorable outcomes and un-
matched durability. Two landmark investigations have not 
only confirmed this performance, but have also proven the 
superiority of Novacor mechanical support to medical therapy, 
as well as set the stage for its next logical application in destina-
tion therapy. The REMATCH trial (Randomized Evaluation 
of Mechanical Assistance for the Treatment of Congestive 
Heart Failure), a multi-center study supported by the National 
Heart, Lung, and Blood Institute, compared long-term implan-
tation of left ventricular assist devices with optimal medical 
management for patients with end-stage heart failure who 
require, but do not qualify to receive, cardiac transplantation. 
One hundred twenty- nine patients were randomly assigned 
to either LVAD support or optimal medical management. 
Survivals at 1 year were 52% in the device group and 25% in 
the medical therapy group (p = .002) and at 2 years 23% and 
8%, respectively (p = 0.09).25 Similarly, an FDA approved, 
prospective, multi-center, non-randomized controlled trial 
called INTrEPID (Investigation in Non – Transplant Eligible 
Patients who are Inotrope Dependent) demonstrated that 
patients receiving a Novacor LVAS had an average survival 
time more than three times longer than control patients who 
received optimal medical therapy but no device.26 In addition, 
patients receiving mechanical support scored significantly 
higher on standard measures of quality of life than patients 
in the control group.16,26
E X P E R T  C O M M E N T A R Y
As one of the most active centers in North America 
utilizing the Novacor LVAS, our institution has found the 
reliability of the Novacor system to be a critical and attrac-
tive feature. Additionally, we have witnessed the dramatic 
decline in cerebrovascular events at our own and other centers 
world-wide following the inflow conduit refinements, briefly 
described earlier in this review. The initial Cooley® conduit 
that was utilized from 1984 to 1998 was fabricated from woven 
low-porosity polyester that contributed to sub-optimal mural 
flow and was prone to radial pulsation from its unsupported 
structural design. This combination resulted in the formation 
of a poorly attached, friable pannus within the graft and con-
sequent propagation of particulate emboli (Fig. 5).
Redesigned in 1998, a Vascutek® (Terumo Company, 
Scotland, UK) inflow conduit was developed from knitted 
gel-sealed uncrimped polyester, yet still suffered from the 
formation of a thin, adherent pannus (Fig. 6). Two years later 
an expanded polytetrafluoroethylene (ePTFE) inflow conduit 
was introduced based on its 25-year history as a proven bio-
compatibible material in vascular applications, with particular 
suitability in the setting of venous flow dynamics (Fig. 7). 
Features include an integrally supported construction with 
an uninterrupted luminal surface not penetrated by sutures, 
and an outer impermeable coating that blocks transmural 
penetration by inflammatory mediators and prevents adhe-
sion formation. The result is a refined inflow conduit that has 
markedly decreased the incidence of embolic CVAs in this 
patient population18,19,24 We prefer the 9-cm model due to op-
timal anti-thrombotic performance evaluated in multi-center 
experience (Fig. 8).20
Our intraoperative management of coagulation involves 
the utilization of an antifibrinolytic agent, a standard cardiop-
ulmonary bypass dose of heparin, and subsequent full reversal 
guided by activated clotting time (ACT) surveillance. In the 
early post-operative period, when chest tube drainage has 
decreased to less than 60 milliliters/hour for 3 consecutive 
FIGURE 5. A) The Cooley inflow conduit was fabricated from 
low-porosity polyester that resulted in  B) a poorly attached, fri-
able pannus.
Figure 6. A) The Vascutek conduit was developed from knitted 
gel-sealed polyester, yet still suffered from the formation of B) a 
thin, adherent pannus.
FIGURE 7. A) The expanded PTFE conduit was developed with 
a smooth surface resulting in a reduced inflammatory response 
and B) no pannus.
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hours, we initiate heparin therapy accompanied by aspirin 
and clopidogrel. Transition to coumadin usually occurs over 
3 to 7 days when platelet function has stabilized and hepatic 
function has returned to near-normal conditions.
Our application of these protocols in combination with ap-
propriate candidate selection and thoughtful surgical planning 
has allowed our patients to benefit from the unmatched dura-
bility of the Novacor LVAS. Recalling its success as the first 
system to surpass six years of support in a single patient, and the 
designation as the first and only device to meet the multi-year 
Device Readiness Test Protocol of the U.S. National Institutes 
of Health, we anticipate similar promise from, and expanded 
utilization of, future generations of WorldHeart devices.
F I V E - Y E A R  V I E W
Patients with end-stage heart disease have many compel-
ling reasons to consider surgical treatment in the current 
era. The next five years, however, will witness a revolution in 
both the way that mechanical support is provided, and in the 
population to which it is applied.
Technologists will focus on the development of new devices 
with smaller sizes, improved longevity, and the transcutaneous 
transfer of energy. WorldHeart is strategically positioned for 
the future with two new devices awaiting the completion of 
clinical trials. The Novacor LVAS II is the next generation 
pulsatile device that is smaller than its predecessor, fully 
implantable, and magnetically driven to eliminate wearing 
elements. This device entered the phase of animal testing in 
2005. Similar enthusiasm also surrounds the WorldHeart Le-
vacor Rotary VAD, which is an advanced, fourth-generation 
continuous flow pump that uses magnetic levitation to fully 
suspend the spinning impeller inside a compact housing. En-
couraging results followed its first clinical use in Europe, and 
have been highlighted by feasibility trials initiated in Canada 
earlier this year.16
Clinicians will be challenged with perhaps the greatest re-
sponsibility for the continued development of surgical therapy 
in heart failure. Commitment to multi-disciplinary education 
and collaborative therapeutic planning amongst different 
specialists will identify patients who can benefit from elective 
rather than urgent mechanical support. Dedicated centers will 
also be able to offer individualized care; although it was felt by 
many that the Novacor was “un-weanable”, in 2005 our institu-
tion was the first in the United States to successfully wean a 
patient from her Novacor LVAS following a viral cardiomy-
opathy, biventricular failure, and cardiogenic shock.
In the future, the innovator, the researcher, the engineer, 
and the physician will continue to work in concert to provide 
assisted circulation to a variety of different patient populations 
in various clinical settings with a spectrum of personalized 
needs, and they will provide this amazing technology one 
failing heart at a time.
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